Related Experiment Video
Updated: Feb 2, 2026

Author Spotlight: Revolutionizing Remote Surgery with Augmented Reality and Robotics for Enhanced Precision and Accessibility
Published on: August 9, 2024
Observed to expected 30-day mortality as a benchmark for transcatheter aortic valve replacement
Matthew C Henn1, Alan Zajarias2, Nishath Quader2
1Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, Mo.
The Society for Thoracic Surgery Predicted Risk of Mortality (STS-PROM) overestimates 30-day mortality after transcatheter aortic valve replacement (TAVR). Achieving an observed-to-expected (O:E) ratio below 0.6 is a realistic goal for TAVR programs.
Area of Science:
- Cardiology
- Interventional Cardiology
- Health Services Research
Background:
- The observed-to-expected (O:E) mortality ratio is a key metric for evaluating transcatheter aortic valve replacement (TAVR) trials.
- Early TAVR trials reported O:E ratios below 0.6 using the Society for Thoracic Surgery Predicted Risk of Mortality (STS-PROM).
- Recent Transcatheter Valve Therapy (TVT) Registry data show O:E ratios around 1.0, creating a discrepancy.
Purpose of the Study:
- To investigate the discordance in O:E ratios for TAVR.
- To evaluate institutional O:E ratios for 30-day mortality after TAVR.
- To compare institutional TAVR outcomes with STS-PROM predictions.
Main Methods:
- Prospective data collection for 546 TAVR patients from 2008-2015, with retrospective review.
- Calculation of observed mortality and STS-PROM to determine O:E ratios.
- Comparison of O:E ratios across various subgroups, including risk strata and procedural approaches.
Main Results:
- The overall 30-day mortality O:E ratio was 0.4, significantly less than 1.
- O:E ratios remained below 0.5 across low, moderate, and high STS-PROM risk groups.
- Transapical TAVR showed a higher O:E ratio (0.8) than transfemoral TAVR (0.2).
- O:E ratios for commercial (0.5) and research (0.3) TAVR patients were similar and significantly less than 1.
Conclusions:
- STS-PROM consistently overestimates 30-day mortality following TAVR.
- An O:E ratio below 0.6 is achievable and may represent a realistic benchmark for TAVR programs.
- Current TVT Registry results may not be representative of optimal commercial TAVR performance; programs exceeding an O:E ratio of 0.6 should reassess their processes.
Related Concept Videos
Expected Value
Naturalistic Observations
Determination of Expected Frequency
Heart Valves
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
Continuous Renal Replacement Therapy
Expected Frequencies in Goodness-of-Fit Tests

